Strong Revenue Growth
Pharming delivered a strong quarter with total revenues growing by 26% in Q2 2025 compared to the same quarter last year. Operating profit reached $12.9 million, a significant turnaround from a loss in the previous year.
RUCONEST and Joenja Performance
RUCONEST revenues grew by 28% year-on-year, reaching $80.4 million. Joenja also saw strong performance with a 15% quarter-on-quarter revenue growth, achieving $12.8 million in net revenue.
Pipeline and Product Expansion
Pharming has expanded its pipeline with the acquisition of KL1333 and ongoing development of Joenja for new indications. Joenja has been successfully launched in the UK, and regulatory applications for label expansion have been filed in Japan and with the FDA.
Upgraded Revenue Guidance
Pharming raised its 2025 total revenue guidance to between $335 million and $350 million, up from the prior guidance of $325 million to $340 million.